TP53 and B-cell chronic lymphocytic leukemia: A similar observation has been made for TP53 aberrations [del(17p) and/or TP53 mutations], where M-CLL patients showed significantly longer time-to-first-tratment (TTFT) and overall survival (OS) compared to U-CLL patients carrying the same genomic aberrations IG (130, 131).